Alturas Minerals Corp
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1997-01-01
- Employees
- 2
- Market Cap
- $476.1M
- Website
- http://www.altimmune.com
- Introduction
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune ...
NasoShield in Healthy Adults to Study Safety and Immunogenicity
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04415749
- Locations
- 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States
Study of the Safety and Immunogenicity of NasoVAX Extension
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03760549
- Locations
- 🇺🇸
Optimal Health Research, Rockville, Maryland, United States
NasoShield Study of Safety and Immunogenicity
- Conditions
- Interventions
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT03352466
- Locations
- 🇺🇸
Optimal Research, LLC, Melbourne, Florida, United States
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03232567
- Locations
- 🇺🇸
Optimal Health Research, Rockville, Maryland, United States
Immune Response Following Seasonal Influenza Vaccination
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03163342
- Locations
- 🇺🇸
Optimal Health Research, Rockville, Maryland, United States
Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02496897
- Locations
- 🇰🇷
SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
🇬🇧Royal Free Hospital, London, United Kingdom
🇬🇧Bradford Teaching Hospitals, Bradford Royal Infirmary, North Yorkshire, United Kingdom
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
- Conditions
- Interventions
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00755703
- Locations
- 🇺🇸
Alabama Vaccine Research Center (UAB), Birmingham, Alabama, United States